A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma

by | Mar 3, 2026 | Clinical Trials | 0 comments

​ Conditions: Advanced Esophageal Squamous Cell Carcinoma

Interventions: Drug: anlotinib combined with benmelstobart; Drug: Toripalimab Combined with Chemotherapy

Sponsors: The First Affiliated Hospital of Zhengzhou University

Not yet recruiting Conditions: Advanced Esophageal Squamous Cell Carcinoma
Interventions: Drug: anlotinib combined with benmelstobart; Drug: Toripalimab Combined with Chemotherapy
Sponsors: The First Affiliated Hospital of Zhengzhou University
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *